IL28B polymorphisms are not associated with the response to interferon-β in multiple sclerosis

J Neuroimmunol. 2011 Oct 28;239(1-2):101-4. doi: 10.1016/j.jneuroim.2011.08.004. Epub 2011 Sep 1.

Abstract

Recent studies have revealed an association between interleukin 28B (IL28B) and response to IFN-alpha treatment in hepatitis C patients. Here we investigated the influence of IL28B polymorphisms in the response to interferon-beta (IFNβ) in multiple sclerosis (MS) patients. We genotyped two SNPs of the IL28B gene (rs8099917 and rs12979860) in 588 MS patients classified into responders (n=281) and non-responders (n=307) to IFNβ. Combined analysis of the study cohorts showed no significant associations between SNPs rs8099917 and rs12979860 and the response to treatment. These findings do not support a role of IL28B polymorphisms in the response to IFNβ in MS patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Cohort Studies
  • Female
  • Genotype
  • Humans
  • Interferon-beta / physiology*
  • Interferon-beta / therapeutic use
  • Interferons
  • Interleukins / genetics*
  • Male
  • Multiple Sclerosis / drug therapy
  • Multiple Sclerosis / genetics
  • Multiple Sclerosis / immunology*
  • Polymorphism, Single Nucleotide*

Substances

  • interferon-lambda, human
  • Interleukins
  • Interferon-beta
  • Interferons